Common variants in PARK loci and related genes and Parkinson's disease

Movement Disorders

Volumn 26, Issue 2, 2011, Pages 280-288

  Chung, Sun Ju ^a,b   Armasu, Sebastian M ^a   Biernacka, Joanna M ^a   Lesnick, Timothy G ^a   Rider, David N ^a   Lincoln, Sarah J ^c   Ortolaza, Alexandra I ^c   Farrer, Matthew J ^c   Cunningham, Julie M ^a   Rocca, Walter A ^a   Maraganore, Demetrius M ^a,d  

^a MAYO CLINIC   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c MAYO GRADUATE SCHOOL   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Age at onset of parkinson's disease; Common genetic variants; PARK loci genes; Parkinson's disease; Susceptibility to parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2;

ADULT; AGED; ARTICLE; ATP13A2 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAPT GENE; ONSET AGE; PARK GENE; PARK2 GENE; PARKINSON DISEASE; PINK1 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SNCB GENE; SNCG GENE; SPR GENE; UCHL1 GENE; UNITED STATES; VARIABLE NUMBER OF TANDEM REPEAT;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; MALE; ODDS RATIO; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; TAU PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 79951474478     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23376     Document Type: Article

References (55)

1. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 2002; 55: 25-31.
2. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
4. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
5. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-452.
6. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
7. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
8. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
9. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-607.
10. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38: 1184-1191.
11. Lautier C, Goldwurm S, Durr A, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet 2008; 82: 822-833.
12. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005; 14: 2099-2111.
13. Maraganore DM, Lesnick TG, Elbaz A, et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004; 55: 512-521.
14. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296: 661-670.
15. Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005; 77: 685-693.
16. Facheris M, Strain KJ, Lesnick TG, et al. UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study. Neurosci Lett 2005; 381: 131-134.
17. Brighina L, Frigerio R, Schneider NK, et al. Alpha-synuclein, pesticides, and Parkinson disease: a case-control study. Neurology 2008; 70(16 Pt 2): 1461-1469.
18. Maraganore DM. Blood is thicker than water: the strengths of family-based case-control studies. Neurology 2005; 64: 408-409.
19. Rocca WA, Maraganore DM, McDonnell SK, Schaid DJ. Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol 1998; 51: 517-523.
20. Hartge P, Brinton LA, Rosenthal JF, et al. Random digit dialing in selecting a population-based control group. Am J Epidemiol 1984; 120: 825-833.
21. Potthoff RF. Telephone sampling in epidemiologic research: to reap the benefits, avoid the pitfalls. Am J Epidemiol 1994; 139: 967-978.
22. Brighina L, Schneider NK, Lesnick TG, et al. Alpha-synuclein, alcohol use disorders, and Parkinson disease: a case-control study. Parkinsonism Relat Disord 2009; 15: 430-434.
23. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
24. Bras J, Simon-Sanchez J, Federoff M, et al. Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum Mol Genet 2009; 18: 341-346.
25. Nichols WC, Kissell DK, Pankratz N, et al. Variation in GIGYF2 is not associated with Parkinson disease. Neurology 2009; 72: 1886-1892.
26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
27. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980: 5-338.
28. Cox DR. Regression models of life-tables (with discussion). J R Stat Soc [Ser B] 1972; 34: 187-220.
29. Maraganore DM, Hernandez DG, Singleton AB, et al. Case-control study of the extended tau gene haplotype in Parkinson's disease. Ann Neurol 2001; 50: 658-661.
30. Mamah CE, Lesnick TG, Lincoln SJ, et al. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. Ann Neurol 2005; 57: 439-443.
31. Mueller JC, Fuchs J, Hofer A, et al. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 2005; 57: 535-541.
32. Mizuta I, Satake W, Nakabayashi Y, et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 2006; 15: 1151-1158.
33. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62: 145-153.
34. Fung HC, Scholz S, Matarin M, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2006; 5: 911-916.
35. Pankratz N, Wilk JB, Latourelle JC, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009; 124: 593-605.
36. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303-1307.
37. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
38. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010; 74: 97-109.
39. O'Brien SJ, Menotti-Raymond M, Murphy WJ, et al. The promise of comparative genomics in mammals. Science 1999; 286: 458-462, 479-481.
40. Murphy WJ, Stanyon R, O'Brien SJ. Evolution of mammalian genome organization inferred from comparative gene mapping. Genome Biol 2001; 2:REVIEWS0005.
41. Brighina L, Okubadejo NU, Schneider NK, et al. Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study. Neurosci Lett 2007; 420: 229-234.
42. Kwok JB, Teber ET, Loy C, et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004; 55: 329-334.
43. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003; 300: 636-640.
44. Fuchs J, Tichopad A, Golub Y, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008; 22: 1327-1334.
45. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 2001; 10: 3101-3109.
46. Chiba-Falek O, Touchman JW, Nussbaum RL. Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum Genet 2003; 113: 426-431.
47. Bonsch D, Lederer T, Reulbach U, et al. Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence. Hum Mol Genet 2005; 14: 967-971.
48. Cronin KD, Ge D, Manninger P, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 2009; 18: 3274-3285.
49. West AB, Maraganore D, Crook J, et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum Mol Genet 2002; 11: 2787-2792.
50. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52: 1214-1220.
51. Rocca WA, Peterson BJ, McDonnell SK, et al. The Mayo Clinic family study of Parkinson's disease: study design, instruments, and sample characteristics. Neuroepidemiology 2005; 24: 151-167.
52. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 2000; 15: 819-825.
53. Kahvejian A, Quackenbush J, Thompson JF. What would you do if you could sequence everything? Nat Biotechnol 2008; 26: 1125-1133.
54. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet 2008; 24: 133-141.
55. Maraganore DM, de Andrade M, Lesnick TG, et al. Complex interactions in Parkinson's disease: a two-phased approach. Mov Disord 2003; 18: 631-636.